Published in Ther Deliv on August 01, 2011
Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery. Breast Cancer Res (2015) 0.87
New findings about iron oxide nanoparticles and their different effects on murine primary brain cells. Int J Nanomedicine (2015) 0.87
Perspectives on the application of nanotechnology in photodynamic therapy for the treatment of melanoma. Nano Rev (2014) 0.87
Technology for Innovation in Radiation Oncology. Int J Radiat Oncol Biol Phys (2015) 0.82
Temperature-dependent and time-dependent effects of hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3: in vitro studies. Int J Nanomedicine (2015) 0.78
Nanoparticle-induced intraperitoneal hyperthermia and targeted photoablation in treating ovarian cancer. Oncotarget (2015) 0.77
Simultaneous hyperthermia-chemotherapy with controlled drug delivery using single-drug nanoparticles. Sci Rep (2016) 0.77
Controlled Heat Stress Promotes Myofibrillogenesis during Myogenesis. PLoS One (2016) 0.75
Hyperthermia and chemotherapy using Fe(Salen) nanoparticles might impact glioblastoma treatment. Sci Rep (2017) 0.75
Recent Advances on Inorganic Nanoparticle-Based Cancer Therapeutic Agents. Int J Environ Res Public Health (2016) 0.75
Hyperthermia enhances 17-DMAG efficacy in hepatocellular carcinoma cells with aggravated DNA damage and impaired G2/M transition. Sci Rep (2016) 0.75
Hyperthermia using nanoparticles - Promises and pitfalls. Int J Hyperthermia (2016) 0.75
Hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3 nanoparticles: in vivo studies. Int J Nanomedicine (2016) 0.75
Monitoring nanoparticle-mediated cellular hyperthermia with a high-sensitivity biosensor. Nanomedicine (Lond) (2014) 0.75
Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus (2016) 0.75
Current Status and Future Direction of Nanomedicine: Focus on Advanced Biological and Medical Applications. Nucl Med Mol Imaging (2016) 0.75
New experimental model for single liver lobe hyperthermia in small animals using non-directional microwaves. PLoS One (2017) 0.75
A comparative study of the adhesion of biosynthesized gold and conjugated gold/prodigiosin nanoparticles to triple negative breast cancer cells. J Mater Sci Mater Med (2017) 0.75
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A (2003) 12.17
Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol (2008) 10.77
Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci U S A (2005) 7.70
Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett (2004) 7.12
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul (2001) 6.59
Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett (2005) 4.19
Ultralong single-wall carbon nanotubes. Nat Mater (2004) 3.83
Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res (2009) 3.77
Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer Lett (2008) 3.20
Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer (2007) 2.83
Selective inductive heating of lymph nodes. Ann Surg (1957) 2.46
Metal nanoshells. Ann Biomed Eng (2006) 2.44
II. Contribution to the Knowledge of Sarcoma. Ann Surg (1891) 2.21
Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency. Int J Radiat Oncol Biol Phys (2005) 2.19
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
In vivo near-infrared mediated tumor destruction by photothermal effect of carbon nanotubes. ACS Nano (2009) 1.88
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev (2009) 1.54
Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles. Cancer (2010) 1.54
Magnetic nanoparticle hyperthermia for prostate cancer. Int J Hyperthermia (2010) 1.50
Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials (2010) 1.49
Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med (2010) 1.43
Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A (2009) 1.41
For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia (1999) 1.27
Gold nanocages for cancer detection and treatment. Nanomedicine (Lond) (2007) 1.26
Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. J Neurooncol (2007) 1.21
Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells. Int J Nanomedicine (2010) 1.19
A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study. BMC Cancer (2010) 1.17
Tumor regression in vivo by photothermal therapy based on gold-nanorod-loaded, functional nanocarriers. ACS Nano (2011) 1.15
Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab (2010) 1.14
Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study. Lab Invest (1994) 1.13
Thermal ablation therapeutics based on CN(x) multi-walled nanotubes. Int J Nanomedicine (2007) 1.09
Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data. Int J Hyperthermia (2010) 1.08
Comparative efficiencies of photothermal destruction of malignant cells using antibody-coated silica@Au nanoshells, hollow Au/Ag nanospheres and Au nanorods. Nanotechnology (2009) 1.04
The role of apoptosis in the response of cells and tumours to mild hyperthermia. Int J Radiat Biol (1991) 1.02
Critical parameters in the pegylation of gold nanoshells for biomedical applications: an in vitro macrophage study. J Drug Target (2009) 1.01
Combination hyperthermia and radiation therapy for malignant melanoma. Cancer (1982) 1.00
High-frequency, magnetic-field-responsive drug release from magnetic nanoparticle/organic hybrid based on hyperthermic effect. ACS Appl Mater Interfaces (2010) 0.99
Towards patient specific thermal modelling of the prostate. Phys Med Biol (2006) 0.98
The in vivo performance of magnetic particle-loaded injectable, in situ gelling, carriers for the delivery of local hyperthermia. Biomaterials (2009) 0.96
Cancer and the heat shock response. Eur J Cancer (1994) 0.96
Influence of Gold Nanoshell on Hyperthermia of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs). J Phys Chem C Nanomater Interfaces (2010) 0.95
Chemoradiation with hyperthermia in the treatment of head and neck cancer. Int J Hyperthermia (2010) 0.94
Changes in oxygenation status and blood flow in a rat tumor model by mild temperature hyperthermia. Int J Radiat Oncol Biol Phys (1999) 0.94
Multifunctionalized gold nanoparticles with peptides targeted to gastrin-releasing peptide receptor of a tumor cell line. Bioconjug Chem (2010) 0.92
Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat. Invest Radiol (1990) 0.92
Attenuation of mouse melanoma by A/C magnetic field after delivery of bi-magnetic nanoparticles by neural progenitor cells. ACS Nano (2010) 0.91
Nanophotothermolysis of multiple scattered cancer cells with carbon nanotubes guided by time-resolved infrared thermal imaging. J Biomed Opt (2009) 0.91
Present and future technology for simultaneous superficial thermoradiotherapy of breast cancer. Int J Hyperthermia (2010) 0.90
Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94-153. Cancer (2010) 0.89
Single-wall carbon nanotubes assisted photothermal cancer therapy: animal study with a murine model of squamous cell carcinoma. Lasers Surg Med (2010) 0.89
A technique for localized heating in tissue: an adjunct to tumor therapy. Med Instrum (1976) 0.88
Lethality in mammalian cells due to hyperthermia under oxic and hypoxic conditions. Int J Radiat Biol Relat Stud Phys Chem Med (1978) 0.88
Induction of deep, local hyperthermia by ultrasound and electromagnetic fields: problems and choices. Radiat Environ Biophys (1980) 0.87
Tumor selectivity of stealth multi-functionalized superparamagnetic iron oxide nanoparticles. Int J Pharm (2010) 0.87
Laparoscopic continuous hyperthermic peritoneal perfusion. J Am Coll Surg (2001) 0.86
Clinical hyperthermia and chemotherapy. Radiol Clin North Am (1989) 0.85
Magnetic nanoparticle-induced hyperthermia treatment under magnetic resonance imaging. Magn Reson Imaging (2010) 0.85
Blood interactions with noble metals: coagulation and immune complement activation. ACS Appl Mater Interfaces (2009) 0.84
Effects of local tumor hyperthermia on the growth of solid mouse tumors. Cancer Res (1979) 0.81
Clinical requirements for localized hyperthermia in the patient. Radiat Environ Biophys (1980) 0.80
Hyperthermia with radiation in the treatment of locally advanced head and neck cancer: a report of randomized trial. J Cancer Res Ther (2011) 0.80
Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells. Future Oncol (2006) 0.79
Ag-doped manganite nanoparticles: new materials for temperature-controlled medical hyperthermia. J Biomed Mater Res A (2009) 0.79
Hyperthermia in the treatment of cancer. Perspectives on its promise and its problems. Cancer (1984) 0.78
Use of combined radiation and hyperthermia for gynecological cancer. Curr Opin Obstet Gynecol (2010) 0.78
Thermoradiotherapy for persistent cancer in previously irradiated fields. Cancer (1986) 0.77
Clinical experience with interstitial thermoradiotherapy for localized implantable pelvic tumors. Am J Clin Oncol (1993) 0.77
Some practical considerations for the use of localized hyperthermia in the treatment of cancer. J Microw Power (1981) 0.76
Combined radiation and hyperthermia: comparison of two treatment schedules based on data from a registry established by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys (1984) 0.76
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys (2012) 2.29
Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol (2012) 2.22
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer (2007) 1.86
Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol (2008) 1.77
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
The dosimetric feasibility of gold nanoparticle-aided radiation therapy (GNRT) via brachytherapy using low-energy gamma-/x-ray sources. Phys Med Biol (2009) 1.61
A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther (2010) 1.58
Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res (2008) 1.57
Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res (2008) 1.55
Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys (2008) 1.50
Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res (2008) 1.45
Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol (2008) 1.43
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol (2011) 1.43
Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med (2010) 1.43
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.43
Concern Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood (2008) 1.42
Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer (2010) 1.42
Estimation of microscopic dose enhancement factor around gold nanoparticles by Monte Carlo calculations. Med Phys (2010) 1.41
Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol (2007) 1.39
Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer (2009) 1.32
Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun (2012) 1.31
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) (2010) 1.30
Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol (2006) 1.29
Correlation between internal fiducial tumor motion and external marker motion for liver tumors imaged with 4D-CT. Int J Radiat Oncol Biol Phys (2007) 1.27
Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys (2009) 1.26
Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol (2010) 1.24
Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys (2007) 1.23
Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol (2010) 1.22
Nanoparticle-mediated thermal therapy: evolving strategies for prostate cancer therapy. Int J Hyperthermia (2010) 1.20
Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol (2011) 1.20
Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol (2009) 1.19
{Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res (2010) 1.17
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys (2006) 1.16
Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem (2007) 1.14
Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol (2008) 1.13
Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys (2009) 1.10
Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol (2008) 1.09
4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. Radiother Oncol (2008) 1.08
Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin Investig Drugs (2007) 1.08
Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 1.06
Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. Clin Cancer Res (2012) 1.05
Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol (2008) 1.04
Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer (2011) 1.02
A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer (2012) 1.00
Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma. Phys Med Biol (2010) 0.99
Plumbagin inhibits proliferative and inflammatory responses of T cells independent of ROS generation but by modulating intracellular thiols. J Cell Biochem (2010) 0.99
Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. Med Dosim (2008) 0.98
Metformin use and improved response to therapy in rectal cancer. Cancer Med (2013) 0.97
Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys (2009) 0.97
Methodology for determining doses to in-field, out-of-field and partially in-field organs for late effects studies in photon radiotherapy. Phys Med Biol (2010) 0.97
Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol (2014) 0.95
Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. Int J Cancer (2011) 0.95
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst (2013) 0.93
Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. Int J Radiat Oncol Biol Phys (2009) 0.92
Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol (2010) 0.91
Integrin αvβ3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomedicine (2011) 0.91
In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy. Int J Nanomedicine (2012) 0.91
Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys (2007) 0.90
Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer (2010) 0.90
Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res (2010) 0.90
Charged-particle therapy for hepatocellular carcinoma. Semin Radiat Oncol (2011) 0.89
Intra-organ Biodistribution of Gold Nanoparticles Using Intrinsic Two-photon Induced Photoluminescence. Lasers Surg Med (2010) 0.89
Laser-induced thermal injury to dermal blood vessels: analysis of wavelength (585 nm vs. 595 nm), cryogen spray cooling, and wound healing effects. Lasers Surg Med (2005) 0.89
Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys (2009) 0.88
Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol (2011) 0.88
Near-infrared narrow-band imaging of gold/silica nanoshells in tumors. J Biomed Opt (2009) 0.87
Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol (2006) 0.86
Narrow band imaging of squamous cell carcinoma tumors using topically delivered anti-EGFR antibody conjugated gold nanorods. Lasers Surg Med (2012) 0.86
Development and validation of a sensitive LC/MS/MS method for the determination of γ-tocotrienol in rat plasma: application to pharmacokinetic studies. Biomed Chromatogr (2012) 0.86
HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance. Mol Cancer Res (2011) 0.86
Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys (2011) 0.86
Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointest Cancer Res (2007) 0.85
Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Int J Cancer (2011) 0.85
Respiratory gating with EPID-based verification: the MDACC experience. Phys Med Biol (2009) 0.84
Recurrent invasive lobular carcinoma presenting as a ruptured breast implant. Radiol Oncol (2011) 0.84
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford) (2013) 0.82
Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol (2009) 0.82
Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience. J Surg Oncol (2014) 0.81